Published in Nat Rev Endocrinol on December 04, 2012
Microarray analyses of glucocorticoid and vitamin D3 target genes in differentiating cultured human podocytes. PLoS One (2013) 0.83
Mechanisms involved in altered bone metabolism in diabetes: a narrative review. J Diabetes Metab Disord (2016) 0.75
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 7.69
Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med (2008) 7.21
Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int (2007) 3.06
Vitamin D levels, microvascular complications, and mortality in type 1 diabetes. Diabetes Care (2011) 1.28
Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int (2011) 1.24
Vitamin D levels and mortality in type 2 diabetes. Diabetes Care (2010) 1.21
Circulating vitamin D metabolites and kidney disease in type 1 diabetes. J Clin Endocrinol Metab (2012) 1.11
Vitamin D deficiency and coronary artery calcification in subjects with type 1 diabetes. Diabetes Care (2010) 1.11
Vitamin D levels and asymptomatic coronary artery disease in type 2 diabetic patients with elevated urinary albumin excretion rate. Diabetes Care (2011) 1.04
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet (2012) 5.10
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet (2012) 4.75
Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int (2008) 3.27
Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care (2003) 3.12
Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ (2004) 2.62
Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int (2011) 2.52
Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study. J Hypertens (2007) 2.27
Urinary proteomics in diabetes and CKD. J Am Soc Nephrol (2008) 2.12
Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Diabetes Care (2003) 2.08
Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care (2010) 2.06
Progression of nephropathy in type 2 diabetic patients. Kidney Int (2004) 2.05
New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet (2012) 1.79
Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes (2009) 1.76
Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med (2010) 1.59
Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy. Kidney Int (2005) 1.52
Development and validation of GFR-estimating equations using diabetes, transplant and weight. Nephrol Dial Transplant (2009) 1.46
Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int (2005) 1.40
Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes (2012) 1.38
Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care (2011) 1.34
Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care (2009) 1.33
Vitamin D levels, microvascular complications, and mortality in type 1 diabetes. Diabetes Care (2011) 1.28
YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care (2008) 1.23
Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care (2009) 1.23
Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care (2006) 1.21
Vitamin D levels and mortality in type 2 diabetes. Diabetes Care (2010) 1.21
initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial. Diabetes Care (2011) 1.18
Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate. Diabetes Care (2008) 1.18
Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care (2008) 1.18
Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care (2010) 1.14
ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol (2008) 1.12
Elevated levels of high-molecular-weight adiponectin in type 1 diabetes. J Clin Endocrinol Metab (2008) 1.12
Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One (2010) 1.12
Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J Hypertens (2010) 1.09
Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. Curr Diab Rep (2013) 1.09
Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care (2007) 1.07
Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study. Kidney Int (2005) 1.06
Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes. Clin Chem (2011) 1.05
Vitamin D levels and asymptomatic coronary artery disease in type 2 diabetic patients with elevated urinary albumin excretion rate. Diabetes Care (2011) 1.04
Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. Diabetes Res Clin Pract (2012) 1.01
The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy. Proteomics Clin Appl (2008) 1.01
Serum uric acid as a new player in the development of diabetic nephropathy. J Ren Nutr (2011) 1.00
Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. Scand J Clin Lab Invest (2008) 1.00
Implementation of proteomic biomarkers: making it work. Eur J Clin Invest (2012) 1.00
Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. PLoS One (2008) 0.98
Urinary neutrophil gelatinase-associated lipocalin and progression of diabetic nephropathy in type 1 diabetic patients in a four-year follow-up study. Nephron Clin Pract (2010) 0.97
Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetes Care (2010) 0.96
Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes. Diabetes Care (2012) 0.95
Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. Diabetes Care (2005) 0.95
Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy. Proteome Sci (2010) 0.95
Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care (2010) 0.94
Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes (2006) 0.93
Cardiovascular autonomic neuropathy and subclinical cardiovascular disease in normoalbuminuric type 1 diabetic patients. Diabetes (2012) 0.93
Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology. PLoS One (2010) 0.89
Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria. Cardiovasc Diabetol (2011) 0.88
Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. Platelets (2010) 0.88
Diabetes mellitus, hypertension and albuminuria in rural Zambia: a hospital-based survey. Trop Med Int Health (2013) 0.87
Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrol Dial Transplant (2011) 0.87
NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis. Cardiovasc Diabetol (2011) 0.86
NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients. Cardiovasc Diabetol (2012) 0.86
Serum amyloid A and C-reactive protein levels may predict microalbuminuria and macroalbuminuria in newly diagnosed type 1 diabetic patients. J Diabetes Complications (2012) 0.86
Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy. J Renin Angiotensin Aldosterone Syst (2011) 0.86
The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP. Scand J Clin Lab Invest (2012) 0.85
Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrol (2010) 0.85
Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol (2011) 0.84
Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study. Diabetologia (2014) 0.84
Tonometric devices for central aortic systolic pressure measurements in patients with type 1 diabetes: comparison of the BPro and SphygmoCor devices. Blood Press Monit (2013) 0.84
Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin? J Hypertens (2013) 0.84
Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. Platelets (2009) 0.83
Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy. Kidney Int (2004) 0.83
Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Kidney Int (2002) 0.83
Smoking and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care (2003) 0.83
Proteomic biomarkers in diabetic nephropathy--reality or future promise? Nephrol Dial Transplant (2010) 0.83
Urinary adiponectin excretion rises with increasing albuminuria in type 1 diabetes. J Diabetes Complications (2013) 0.83
SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetes. Diabetologia (2014) 0.82
Association of the pattern recognition molecule H-ficolin with incident microalbuminuria in an inception cohort of newly diagnosed type 1 diabetic patients: an 18 year follow-up study. Diabetologia (2014) 0.82
Finding diabetic nephropathy biomarkers in the plasma peptidome by high-throughput magnetic bead processing and MALDI-TOF-MS analysis. Proteomics Clin Appl (2010) 0.82
Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant (2002) 0.81
Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Semin Nephrol (2004) 0.81
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol (2015) 0.81
High YKL-40 levels predict mortality in patients with type 2 diabetes. Diabetes Res Clin Pract (2011) 0.81
Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria. Amino Acids (2011) 0.80
24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes - a cross-sectional study. Cardiovasc Diabetol (2013) 0.80
Quantitative iTRAQ-Based Proteomic Identification of Candidate Biomarkers for Diabetic Nephropathy in Plasma of Type 1 Diabetic Patients. Clin Proteomics (2010) 0.80
Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. J Renin Angiotensin Aldosterone Syst (2012) 0.80
Renoprotection with and without blood pressure reduction. Kidney Int Suppl (2005) 0.80
Vitamin D status and 5-year changes in urine albumin creatinine ratio and parathyroid hormone in a general population. Endocrine (2013) 0.79
Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial. Nephrol Dial Transplant (2009) 0.79
The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes. J Negat Results Biomed (2011) 0.79
Renoprotective effects of renin-angiotensin-system inhibitors. Lancet (2006) 0.79
Ambulatory tonometric blood pressure measurements in patients with diabetes. Diabetes Technol Ther (2012) 0.79
Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction? Nephrol Dial Transplant (2006) 0.79
Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes. J Hypertens (2015) 0.78
Endothelial progenitor cells in long-standing asymptomatic type 1 diabetic patients with or without diabetic nephropathy. Nephron Clin Pract (2011) 0.78
Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. Diabetes Care (2006) 0.78